Zealthy

About Zealthy

Zealthy is a newer entrant, founded in 2022, but has scaled remarkably fast — the company reports over 200,000 prescriptions written to date. The platform offers both semaglutide and tirzepatide in compounded and brand-name formulations, with monthly pricing spanning a wide range from $39 to $299. That entry point is among the lowest in the industry and reflects Zealthy’s aggressive pricing strategy aimed at making GLP-1 therapy accessible to a broader patient population.

Trust metrics for Zealthy are mixed. On Trustpilot, the platform holds a 3.2 rating across 5,940+ reviews, a moderate score that suggests inconsistent patient experiences. The D- BBB rating adds to the concern, indicating a pattern of unresolved complaints. For a company processing the volume Zealthy claims, these trust indicators suggest growing pains — the infrastructure may not have scaled as smoothly as patient acquisition. Prospective patients should weigh the attractive pricing against this reality.

Clinically, Zealthy positions itself as an all-in-one care platform with a high-support model. Patients have access to nutrition coaching and dietitian consultations, services that most competitors either charge extra for or do not offer at all. The company also provides an insurance billing option, meaning patients with qualifying coverage may be able to use their health insurance to offset costs — a meaningful differentiator in a market dominated by cash-pay models. The combination of both semaglutide and tirzepatide gives patients medication flexibility that many providers lack.

The all-in-one model extends to Zealthy’s platform design. Patients can manage prescriptions, schedule consultations, track progress, and access educational resources through a single interface. For patients who find the fragmented nature of telehealth frustrating — one app for the doctor, another for the pharmacy, a third for coaching — Zealthy’s integrated approach simplifies the experience. The nutrition coaching component is particularly valuable during the early weeks of GLP-1 therapy, when dietary adjustments can significantly reduce side effects and improve outcomes.

Zealthy’s challenge is trust. The combination of rapid growth, aggressive pricing, a D- BBB rating, and a middling Trustpilot score creates uncertainty about whether the clinical experience matches the marketing. We have seen this pattern before with fast-scaling telehealth companies: the product can be genuinely good, but operational growing pains in customer service and fulfillment drag down public perception. Patients who choose Zealthy should do so with realistic expectations about response times and should document all communications with their provider team.

Zealthy GLP-1 Medications

At a Glance